Today: 7 February 2026
Subscribe
Browse Category

Mergers & Acquisitions News 20 December 2025 - 21 December 2025

Warner Bros. Discovery (WBD) Stock Week Ahead: Netflix Deal vs. Paramount Tender Offer Keeps Shares in “Merger-Arbitrage Mode”

Warner Bros. Discovery (WBD) Stock Week Ahead: Netflix Deal vs. Paramount Tender Offer Keeps Shares in “Merger-Arbitrage Mode”

Dateline: December 21, 2025 (Week Ahead: Dec. 22–26, 2025) Warner Bros. Discovery, Inc. Series A stock (NASDAQ: WBD) heads into a holiday-shortened week with the kind of headline-driven volatility that rarely shows up in “normal” media earnings models. The reason is simple: WBD is now trading less like a traditional entertainment company and more like a live deal—anchored between two competing paths to a potential takeover. On Friday’s close, WBD finished around $27.77, putting it almost exactly on top of the $27.75 per-share headline value Netflix is pitching to WBD shareholders—while still leaving a meaningful gap to Paramount Skydance’s $30.00
21 December 2025
······
Salesforce (CRM) Stock Week Ahead: Qualified Acquisition, Agentforce Meets ChatGPT, and Analyst Price Targets to Watch (Dec. 22–26, 2025)

Salesforce (CRM) Stock Week Ahead: Qualified Acquisition, Agentforce Meets ChatGPT, and Analyst Price Targets to Watch (Dec. 22–26, 2025)

Salesforce, Inc. (NYSE: CRM) heads into the Christmas holiday week with a busy backdrop for investors: fresh product distribution news for its Agentforce platform, a newly announced acquisition aimed at “agentic” marketing, and a market calendar that’s likely to amplify day-to-day volatility simply because liquidity is thinner than usual. As of Sunday, December 21, 2025, the latest available trade data puts Salesforce stock around $259.91, following Friday’s (Dec. 19) close. StockAnalysis For the coming week, CRM stock is less about an earnings catalyst (Salesforce just reported) and more about how investors handicap AI monetization, M&A integration, and macro-driven risk appetite
21 December 2025
····
BioMarin (BMRN) Stock Jumps on $4.8 Billion Amicus Deal: Latest News, Forecasts and Analyst Outlook for Dec. 21, 2025

BioMarin (BMRN) Stock Jumps on $4.8 Billion Amicus Deal: Latest News, Forecasts and Analyst Outlook for Dec. 21, 2025

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) is ending 2025 with a bang. Shares surged on Friday, December 19, closing at $61.15—up 17.71% on the day—after the company announced a $4.8 billion all-cash acquisition of rare-disease peer Amicus Therapeutics. Trading volume spiked to roughly 18.5 million shares, far above BioMarin’s recent daily activity, underscoring how dramatically the market repriced the story in a single session. Investing.com+2Reuters+2 As of Sunday, December 21, 2025, the weekend narrative around BioMarin stock is dominated by that deal—and what it signals: a sharper pivot toward durable rare-disease commercial franchises, an attempt to reduce dependence on BioMarin’s fast-growing
21 December 2025
······
Amicus Therapeutics Stock (FOLD) News: BioMarin’s $14.50 Cash Buyout, Deal Timeline, and the Latest Forecasts (Dec. 21, 2025)

Amicus Therapeutics Stock (FOLD) News: BioMarin’s $14.50 Cash Buyout, Deal Timeline, and the Latest Forecasts (Dec. 21, 2025)

As of Sunday, December 21, 2025, Amicus Therapeutics, Inc. (NASDAQ: FOLD) has effectively shifted from a “biotech story stock” to a deal-driven stock. The reason is simple and decisive: BioMarin Pharmaceutical (NASDAQ: BMRN) agreed to acquire Amicus in an all-cash transaction priced at $14.50 per share, putting a hard cap on the near-term upside—unless a competing bid emerges. SEC+1 With U.S. markets closed for the weekend, the most recent close available is $14.18 (Dec. 19, 2025)—a roughly 30% one-day jump that pushed shares close to the deal price and turned the remaining gap into a classic merger-arbitrage spread. StockAnalysis Below
21 December 2025
······
Pharma Stocks Week Ahead (Dec. 22–26, 2025): Drug-Pricing Deals, FDA Catalysts, and M&A to Watch

Pharma Stocks Week Ahead (Dec. 22–26, 2025): Drug-Pricing Deals, FDA Catalysts, and M&A to Watch

Christmas week is usually about thin liquidity and shorter trading hours, not blockbuster headlines. But pharma and biotech stocks head into the final full week of the year with a rare mix of policy shockwaves, deal-making, and FDA-driven volatility—all clustered around Dec. 19–21, 2025. From the White House’s sweeping “most-favored-nation” (MFN) push on U.S. drug prices to BioMarin’s largest-ever acquisition and fresh FDA approvals, the setup into year-end has become more headline-sensitive than the calendar would suggest. Here’s what investors and traders should be watching in pharma stocks in the week ahead. Christmas week trading: shorter sessions, fewer buyers, faster
21 December 2025
···········
Amicus Therapeutics (FOLD) Stock Today: BioMarin’s $4.8B Cash Buyout at $14.50 Resets the Outlook (Dec. 20, 2025)

Amicus Therapeutics (FOLD) Stock Today: BioMarin’s $4.8B Cash Buyout at $14.50 Resets the Outlook (Dec. 20, 2025)

December 20, 2025 — Amicus Therapeutics, Inc. (NASDAQ: FOLD) has abruptly shifted from a “rare-disease growth story” to a merger-arbitrage stock after BioMarin Pharmaceutical announced a definitive, all-cash acquisition valued at roughly $4.8 billion. The headline number for shareholders: $14.50 per share in cash, a premium of about 33% to Amicus’ prior close. Reuters+2BioMarin Corporate+2 On December 19, FOLD shares surged and closed at $14.18, just below the cash consideration—leaving a small spread that now reflects time to close, regulatory clearance, and deal risk rather than day-to-day biotech sentiment. Finviz+1 Below is a comprehensive roundup of the latest news, forecasts,
20 December 2025
······
ServiceNow (NOW) Stock News on Dec. 20, 2025: Armis Deal Rumors, 5-for-1 Split, Analyst Targets and the 2026 Outlook

ServiceNow (NOW) Stock News on Dec. 20, 2025: Armis Deal Rumors, 5-for-1 Split, Analyst Targets and the 2026 Outlook

ServiceNow, Inc. (NYSE: NOW) heads into the weekend with investors still digesting one of the most turbulent stretches the enterprise software leader has seen this year: a fresh stock split, a confirmed AI acquisition closing, and intense market debate over whether a rumored $7 billion cybersecurity deal would be a smart strategic leap—or an expensive distraction. As of Saturday, Dec. 20, 2025, U.S. markets are closed. The most recent session (Friday, Dec. 19) ended with ServiceNow shares at $155.31, up 1.26% on the day, with trading volume jumping to roughly 25.1 million shares—far above recent averages. StockAnalysis+1 That modest Friday
20 December 2025
·····
Tether-Linked Buyers Close $200 Million Peak Mining Deal as Rumble Pursues $767 Million Northern Data Takeover

Tether-Linked Buyers Close $200 Million Peak Mining Deal as Rumble Pursues $767 Million Northern Data Takeover

December 20, 2025 — Newly surfaced U.S. regulatory filings are putting sharper names and structures behind a $200 million divestment at the center of Tether’s expanding push from crypto into AI infrastructure. Peak Mining—the bitcoin-mining business that German AI and data center operator Northern Data agreed to sell—has been acquired by three entities listed in filings as Highland Group Mining Inc., Appalachian Energy LLC, and 2750418 Alberta ULC, just as Tether-backed video platform Rumble presses ahead with an all-stock plan to acquire Northern Data. SEC+1 The convergence of deals matters because Northern Data is majority-owned by a Tether entity, and
20 December 2025
······
BioMarin (BMRN) Stock Surges on $4.8B Amicus Deal: Latest News, Analyst Forecasts, and What to Watch Next (Dec. 20, 2025)

BioMarin (BMRN) Stock Surges on $4.8B Amicus Deal: Latest News, Analyst Forecasts, and What to Watch Next (Dec. 20, 2025)

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) ended Friday’s session sharply higher after announcing a blockbuster rare-disease acquisition that immediately reframed the company’s growth story. Shares closed at $61.15, up about 17.7% on the day, with trading volume far above typical levels—classic “big-news repricing” behavior. Yahoo Finance The catalyst: BioMarin’s agreement to buy Amicus Therapeutics (NASDAQ: FOLD) for $14.50 per share in cash, valuing the deal at approximately $4.8 billion. BioMarin says the acquisition adds two marketed, growing therapies—Galafold (Fabry disease) and Pombiliti + Opfolda (Pompe disease)—plus U.S. rights to DMX-200 (a Phase 3 kidney-disease asset), while also resolving a key piece
20 December 2025
····
Amicus Therapeutics Stock (FOLD) Surges as BioMarin Agrees to Buy the Rare-Disease Biotech for $4.8 Billion

Amicus Therapeutics Stock (FOLD) Surges as BioMarin Agrees to Buy the Rare-Disease Biotech for $4.8 Billion

December 20, 2025 — Amicus Therapeutics, Inc. (NASDAQ: FOLD) is suddenly trading like a classic merger-arbitrage stock after BioMarin Pharmaceutical (NASDAQ: BMRN) agreed to acquire the company in an all-cash deal valued at roughly $4.8 billion. BioMarin’s offer of $14.50 per share sparked a sharp re-pricing of Amicus shares, which have been hovering just below the bid as investors weigh deal timing, closing risk, and what the buyout means for Amicus’ two commercial rare-disease franchises—Galafold (Fabry disease) and Pombiliti + Opfolda (Pompe disease). SEC+1 Below is a detailed breakdown of the latest news (as of 20.12.2025), plus the most relevant
20 December 2025
·····
DJT Stock News Today: Trump Media & Technology Group Jumps on $6B TAE Fusion Merger—Price, Forecasts, and Key Risks (Dec. 20, 2025)

DJT Stock News Today: Trump Media & Technology Group Jumps on $6B TAE Fusion Merger—Price, Forecasts, and Key Risks (Dec. 20, 2025)

Dec. 20, 2025 — Trump Media & Technology Group Corp. (NASDAQ: DJT) is back in the spotlight after announcing a surprise all-stock merger with nuclear fusion company TAE Technologies—a deal the companies describe as valued at more than $6 billion and aimed at accelerating the buildout of a utility-scale fusion power plant. GlobeNewswire+1 The announcement sparked a sharp rally in DJT stock, which surged more than 40% on Dec. 18 and remained highly active as traders repositioned around what many see as a dramatic pivot: from a money-losing social media business to a long-dated, high-uncertainty bet on the future of
20 December 2025
····
Trump Media (DJT) Stock Jumps After $6 Billion Fusion Merger Plan: Latest News, Forecasts, and What Investors Are Watching (Dec. 20, 2025)

Trump Media (DJT) Stock Jumps After $6 Billion Fusion Merger Plan: Latest News, Forecasts, and What Investors Are Watching (Dec. 20, 2025)

Trump Media & Technology Group Corp. (NASDAQ: DJT) is ending the week the way it often lives: loudly, unpredictably, and with traders glued to their screens. After announcing a surprise plan to merge with nuclear fusion developer TAE Technologies in a deal valued at more than $6 billion, DJT shares ripped higher on massive volume—turning a social-media stock into (at least on paper) a new way to bet on the race to power the AI era. GlobeNewswire+2StockAnalysis+2 As of the latest close Friday, Dec. 19, 2025, DJT finished at about $16.09, following a two-day surge that featured a roughly +42%
20 December 2025
·····
1 … 4 5 6 7 8 … 34

Stock Market Today

Seagate (STX) stock jumps nearly 6% as Citi hikes target — what to watch next week

Seagate (STX) stock jumps nearly 6% as Citi hikes target — what to watch next week

7 February 2026
Seagate shares rose 5.9% to $429.32 Friday after Citigroup raised its price target to $480 and reiterated a buy rating. The gain ended a two-day slide but left the stock 6.6% below its Feb. 3 high. CEO Dave Mosley sold 20,000 shares on Feb. 2 under a pre-arranged plan, SEC filings show. U.S. jobs and inflation data next week are seen as key tests for tech stocks.
Cummins (CMI) stock price rebounds after earnings whipsaw as investors eye data-center power demand

Cummins (CMI) stock price rebounds after earnings whipsaw as investors eye data-center power demand

7 February 2026
Cummins shares jumped 6.8% to $577.73 Friday, recovering from a nearly 9% post-earnings drop the day before. The company reported Q4 revenue up 1% to $8.54 billion, took a $218 million charge tied to its hydrogen business, and guided for 2026 EBITDA of 17–18% of sales. Demand for data center generators offset weakness in North American truck markets. Analyst reaction was mixed; Truist raised its price target.
Corning stock hits first record close since 2000 as jobs, CPI data loom

Corning stock hits first record close since 2000 as jobs, CPI data loom

7 February 2026
Corning shares surged 8.3% to $122.16 Friday, their highest close since the dot-com era, after Meta agreed to buy up to $6 billion in fiber-optic cables. The stock is up 40% since late 2025, fueled by strong first-quarter guidance and AI data-center demand. Insiders sold shares following the rally, SEC filings show. Investors await next week’s U.S. jobs and inflation data for rate signals.
Go toTop